Distinguishing Hype from Real Value
Personalization and omnichannel marketing have dominated biopharma brand strategy for years, yet most brands have little to show for it.
Despite more health content, data and channels than ever before, patients and healthcare professionals (HCPs) still lack access to the right health information.
That’s because for many brands, “omnichannel” has too often meant publishing the same static content across different channels.
of HCPs think digital pharma content is repetitive or irrelevant.
But whether biopharma is ready for it or not, AI is changing the game, shifting how patients and HCPs seek and act on health information. Instead of sifting through static pages on a brand.com, asking a rep or waiting for a doctor’s appointment, patients and HCPs are increasingly turning to AI for answers, delivered on demand in a consumerized and frictionless way.
This behavioral shift has raised the bar for biopharma engagement faster than most brand teams anticipated. But this disruption is good news for commercial teams. For the first time, the tools exist to deliver true personalization and omnichannel engagement. We’re closer than ever before to getting HCPs and patients the right information at the precise moment of need, across any channel, based on their specific intent and need.
This new engagement model also generates unprecedented insights into HCP and patient behavior, going much deeper than anything that can be gleaned from static websites or mass emails. With this real-time, granular feedback, brand teams can develop sharper and more impactful commercial strategies.
But as AI interest has surged across commercial biopharma, so too have vendors selling nothing but hype. That vendor noise is also driving a second trend: Brand teams, fatigued from endless product pitches, assume building AI in-house is an easier approach.
However, doing so introduces a new set of challenges, including system maintenance, product innovation, and security. Given that 67% of AI solutions built in-house fail, working with an AI vendor is the right approach for most; the challenge is choosing the right one. Distinguishing genuine capability from shallow marketing puffery has become an essential skill for brand and omnichannel leaders.
New solutions are entering the market every day, and identifying red flags early can save brand teams significant time and budget. Here is what to watch for:
AI that generates new responses not based on 100% MLR-approved content or claims
AI positioned as a replacement for human judgment
AI that isn’t built to ensure compliance with biopharma regulatory regimes, including compliance-by-design with FDA regulations and key privacy and AI regulations
AI optimized for vanity metrics like more clicks, messages, or impressions, with no meaningful measure of true engagement, like faster answers and completing the next best action
Solutions tied to a single channel that ignore how HCPs and patients actually move across touch points
The most important test is whether the AI solution acts as a true intelligence layer, not a standalone feature. Does it actually change how HCPs and patients get fast, relevant answers to real healthcare questions? The right solution can interpret intent, surface approved information, guide the next best step and route to the right human team when it can’t answer safely or compliantly. Importantly, it evolves alongside rapidly changing AI and healthcare regulations, thus ensuring compliance.
The most important compliance question to ask of any AI solution is also the simplest: How does it generate answers? If the AI solution is leveraging anything other than medical, legal, and regulatory (MLR)-approved materials, it’s not the right choice.
AI can synthesize, summarize, and paraphrase with ease. But any outputs that do not tie back to 100% MLR-approved language can introduce off-label or incorrect messages, risking brand integrity, compliance, and even patient outcomes. That risk is not theoretical: in a 2026 study of public AI chatbots, problematic medical responses appeared in as many as 43.2% of answers.
The right AI solutions pull answers directly from approved source materials and trace every response — down to the word — back to a specific asset. When a question falls outside of these assets, the system routes to the appropriate person — whether a rep, medical professional, or administrator — instead of improvising.
In addition to compliant information retrieval, compliant AI has to stay up-to-date with the content life cycle. When a brand team updates a claim, revises an indication or removes an asset, the AI must be able to reflect those changes. Any system that could potentially surface outdated content from cached memory is a regulatory risk.
How to Evaluate
Does the tool generate answers based ONLY on MLR-approved content, or does it generate new, unapproved outputs?
Can every answer be traced back to an approved source, with full auditability?
When a question falls outside approved materials, does it escalate to the right person or resource?
Can it detect adverse event queries and route them appropriately?
Genuine personalization means understanding what a specific person needs at a specific moment in their journey, and shaping the experience around that.
High-value AI identifies intent and orchestrates a seamless experience accordingly. Is this clinician looking for safety data or reimbursement support? Is this patient newly diagnosed or experiencing a side effect mid-treatment and seeking answers? Is this caregiver trying to understand their loved one’s treatment or navigate a coverage denial? The content that surfaces, the sequence that follows, and the recommended next step should all adapt to those answers.
AI-powered personalization also needs to hold across channels. An HCP who engages via email and then visits a brand site should experience a coherent, continuous journey. Broken experiences across touch points erode trust. Before AI, achieving that consistency was out of reach. Now it is possible.
Brand teams that get this right gain something valuable in return. Because AI actively interacts with HCPs and patients, it captures what questions get asked, where people get stuck, and which content moves them to action.
How to Evaluate
Can the AI detect where someone is in their journey and adjust the experience accordingly?
Does it understand the difference between a safety concern and an efficacy question?
Does it personalize the experience across the web, email, SMS, and LLMs?
Does personalization stay within compliance guardrails and approved content?
Case Study
Turning a static patient website into a personalized treatment journey with Ostro Sites for Patients
A top-five biopharma company needed to improve the patient experience for a complex psychiatric treatment with a difficult dosing schedule. Patients and caregivers were struggling to navigate a generic brand site. The brand implemented Ostro Sites for Patients, turning the static patient site into a personalized, dynamic experience. Ostro Sites for Patients analyzed each visitor’s behavior in real time to surface the right approved content instantly.
Faster access to key resources
Increase in engagement with key content
First-party patient insights generated
Beyond the engagement metrics, the brand gained real visibility into what patients were searching for and where they were getting stuck, helping drive their ongoing marketing priorities.
AI creates the opportunity to unify engagement around intent and need rather than channels. After all, HCPs and patients do not think in channels. When they have a question and need an answer, the channel is wherever they are seeking information.
A well-designed AI solution centers on the experience, not channel performance. The right measure of success is whether the person got the information they needed and took the right next step, not whether the email drove opens or the website drove clicks.
In this new framing, omnichannel engagement is education-centric, not campaign-centric. Traditional engagement metrics tell you what happened: impressions, clicks, reach. AI tells you why, identifying the questions that come up repeatedly, the places where HCPs and patients drop off, the content that changes behavior, and the barriers that block adoption or treatment adherence.
With AI in the picture, the measures of success become comprehension and action. Did an HCP find what they needed and complete a high-value action, like setting up a rep call? Did a patient complete enrollment or access cost support? These outcomes matter more than vanity metrics.
How to Evaluate
Does it simplify your omnichannel strategy, rather than add another layer to manage?
Does it provide behavioral intelligence that informs commercial strategy, not just engagement reporting?
Does the platform optimize around outcomes rather than channel activity (clicks, opens)?
Biopharma does not have a content problem; it has an access problem. Most brands have a substantial library of clinically reviewed, MLR-approved materials covering dosing, efficacy, access, and support. But brand teams could keep generating new content indefinitely and it would not solve the core issue: Namely, that patients and HCPs cannot find what already exists.
That’s because content is scattered across brand sites, PDFs, and patient portals, organized for storage rather than retrieval. HCPs do not have time to dig through a website while a patient is waiting. Meanwhile, patients often cannot parse complex clinical documents on their own, as only 12% of Americans have proficient health literacy skills. And traditional keyword-based search struggles to accurately answer nuanced, clinically specific queries. Some of the most valuable approved content produced by a brand goes largely unseen.
The right AI solution turns existing MLR-approved content into a dynamic, queryable knowledge base accessible from any channel. An HCP asks a clinical question and gets an accurate, approved answer in seconds. A patient describes their experience and is guided to the right resource.
This is also where the omnichannel promise becomes real, in the form of a single compliant knowledge base powering web, email, and SMS. That means the same accurate, approved content is available whenever and wherever someone engages, without the inconsistencies that come from managing separate assets across channels.
How to Evaluate
Can it work with real-world content like unstructured PDFs, image-heavy documents, and complex regulatory materials?
Does it adapt content to patients and HCPs based on intent?
Does it reduce the need to create new assets and surface the value of what already exists?
The best AI solutions are built with human involvement as a core part of the experience, rather than an afterthought, and are smart enough to know exactly when to defer to those expert people. Off-label inquiries, dosing questions that go beyond approved statements, complex coverage denials, and anything requiring clinical assessment all fall outside the scope of what AI should handle.
Just as important as the handoff is the context. AI should provide the human expert, whether it’s a nurse navigator, commercial rep, or MSL, with a clear summary of the question and where AI couldn’t resolve the inquiry.
Throughout the entire journey, the HCP and patient should always have a clear understanding of whether they’re interacting with AI or a human. Failing to disclose this is both a compliance and trust issue.
How to Evaluate
Does the system know when to escalate to a human, and can it route users to different pathways based on the nature of their inquiry?
Does the handoff provide the human expert with full context and intent?
Does the solution clearly tell patients and HCPs when they are interacting with AI?
Does it route adverse event queries to humans instead of attempting to answer?
Case Study
Delivering seamless human support beyond approved assets with Veeva Ostro
A brand team supporting 1,000+ patients needed higher-touch support for administration questions, side effects, and coverage complexity. The brand implemented Ostro Sites for HCPs plus Ostro Live Nurse Navigator, combining AI-based guidance with 1:1 nurse support embedded directly on the patient site. When a patient’s needs go beyond what approved content can address, they are routed to a trained nurse navigator who provides direct support. Veeva Ostro stood up the complete system in just two weeks.
Improvement in brand sentiment
Of patients received live 1:1 support
Faster to launch than building in-house
The patient support service is embedded directly onto the patient brand.com for live guidance whenever needed — reducing a 4+ month build to just 4 weeks.
When HCPs and patients have a question, they look for an answer wherever they happen to be, whether on brand.com or in an email or in a conversation with a rep. The problem is that most of those touch points still behave like static content libraries.
It’s no surprise that, according to a recent survey, 65% of HCPs reduced or stopped engaging with biopharma because digital communications felt over-promotional and unhelpful.
The right AI solution puts the HCP and patient first, operating as a conversational intelligence layer that provides a continuous, high-quality experience regardless of channel. This approach shifts engagement from static to conversational. Instead of pushing content out, the right AI solution enables real dialogue.
How to Evaluate
Does the platform maintain context across channels?
Can HCPs and patients ask follow-up questions and get precise, approved answers? Or does the experience “dead-end”?
Does it focus on answering specific HCP/patient questions, or does it prioritize pushing promotional content at them?
Given the complexity of these requirements, some organizations have pursued internal AI builds. But building from scratch is a far more demanding undertaking than it appears, and comes with significant challenges:
Content Governance
Ensuring the AI only serves current, MLR-approved content and reflects updates immediately when claims change or assets are pulled falls entirely on internal teams.
Content Orchestration
Engineering an AI system sophisticated enough to match the right approved content to the right person based on intent and journey stage is a genuinely complex technical challenge.
Keeping Pace with AI Regulations
AI guidance is emerging from multiple directions, not just from the FDA. This is layered on top of an increasingly complicated patchwork of privacy and security requirements.
Specialized Talent
Building an in-house tool requires hiring advanced AI talent across engineering, product, and UX/UI who must navigate the nuances of biopharma commercialization.
Ongoing Cost
The upfront build is expensive, but ongoing maintenance, updates, and infrastructure costs are often what catch teams off guard. Total cost of ownership is much higher than expected.
Pace of AI Evolution
AI technology is moving fast. Whatever gets built today may need significant rearchitecting within 12 to 18 months just to stay current.
For most organizations, the better path is partnering with a solution purpose-built for the compliance and clinical complexity of life sciences.
The omnichannel promise that has anchored biopharma commercial strategy for years is no longer out of reach. The tools exist to get HCPs and patients the right approved content, at the right moment and across every channel, with humans in the loop when it matters.
The key is finding a solution that operates as a true intelligence layer, one that orchestrates the full experience to drive better outcomes for HCPs and patients.
That is what we built Veeva Ostro to be. From AI-powered web and email engagement to live nurse navigator support, Veeva Ostro helps advance HCP and patient engagement.
Learn more
.svg)